Amendments to the Claims

The listing of claims set forth below will replace all prior versions and listings of claims in the application.

1. (Currently Amended) ~~Dermal~~ A dermal application system, which is a self-adhesive matrix system, ~~comprising~~ consisting of aminolaevulinic acid (ALA) ~~ALA~~ derivative crystals suspended in a polymer matrix, wherein the ALA derivative ~~crystals are~~ is an aminolaevulinic acid salt or an aminolaevulinic acid ester or a salt thereof, wherein a substantial amount of the crystals of the ALA derivative have a mean diameter of 20 μm to 200 μm, wherein the ALA ester is a compound of the general formula



wherein R1 is an unsubstituted alkyl group, and each of R2 independently from one another represents a hydrogen atom or an unsubstituted alkyl group.

2. (Previously Presented) Application system according to claim 1, characterised in that the polymer matrix is water-permeable.

3. (Previously Presented) Application system according to claim 1 or 2, characterised in that the polymer matrix is selected from polymers from the group consisting of

a) acrylates,

b) silicon polymers and

c) polyisobutylene.

4. (Currently Amended) Application system according to claim 1, characterised in that a substantial amount of the crystals of the ALA derivative have a mean diameter of 30 μm to 190 μm.

5. (Currently Amended) Application system according to claim 4, characterised in that a substantial amount of the crystals of the ALA derivative have a mean diameter of 90 μm to 160 μm.

6. (Previously Presented) Application system according to claim 1, characterised in that the aminolaevulinic acid derivative is present in a concentration of 1 to 50 wt. % relative to the polymer matrix.

7. (Previously Presented) Application system according to claim 4, characterised in that the polymer matrix consists of Eudragit® NE (NE) (ethyl acrylate-methyl methacrylate-copolymerisate) and acetyl tributyl citrate (ATBC) in the weight ratio NE/ATBC of 1:0.5 to 1:2.5, wherein the aminolaevulinic acid derivative is present in a concentration of 1 to 50 wt. % relative to the polymer matrix.

8. (Canceled)

9. (Previously Presented) Application system according to claim 1, characterised in that it releases at least 30% of the ALA derivative within 30 minutes.

10-12. (Canceled)

13. (Currently Amended) Application system according to claim 1 ~~claim 10~~, characterised in that the alkyl group has 1 to 10 carbon atoms.

14. (Currently Amended) A dermal application system, which is a self-adhesive matrix system, ~~comprising~~ consisting of aminolaevulinic acid (ALA) derivative crystals suspended in a polymer matrix, wherein the ALA derivative is an aminolaevulinic acid salt or an aminolaevulinic acid ester or a salt thereof, wherein a substantial amount of the crystals of the ALA derivative have a mean diameter of 20 µm to 200 µm, wherein ~~Application system according to claim 10, characterised in that~~ the ALA derivative is 5-amino levulinic acid methyl ester, 5-amino levulinic acid ethyl ester, 5-amino levulinic acid propyl ester, 5-amino levulinic acid butyl ester, 5-amino levulinic acid pentyl ester, 5-amino levulinic acid hexyl ester, 5-amino levulinic acid heptyl ester, 5-amino levulinic acid octyl ester, or a pharmaceutically acceptable salt thereof.

15-22. (Canceled)